Active Biotech

Teva, Active Biotech release results from 3-year ALLEGRO study in MS

Friday, March 22, 2013

Teva Pharmaceutical Industries, a global pharmaceutical company, and Active Biotech, a biotechnology company with focus on autoimmune/inflammatory diseases and cancer, released today top-line results from the open-label extension of the phase III ALLEGRO study that assessed the progression of disability and safety of oral laquinimod in early versus delayed-start relapsing-remitting multiple sclerosis (RRMS) patients.

[Read More]